Read by QxMD icon Read


Islam Ghazi, Yukihiro Hamada, David P Nicolau
PURPOSE: The physical compatibility of commonly used agents that could be coadministered in the clinical setting with tedizolid phosphate during Y-site administration was evaluated. METHODS: Tedizolid phosphate vials were reconstituted to a final concentration of 0.8 mg/mL. All other drugs were prepared according to manufacturers' recommendations and diluted with 0.9% sodium chloride injection (where applicable) to the highest standard concentrations used clinically...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
Santiago Pérez-Parra, Alejandro Peña-Monje, Juan Luis Recio, Federico García-García
No abstract text is available yet for this article.
October 12, 2016: Enfermedades Infecciosas y Microbiología Clínica
Vaishali Gaikwad, Tejash Gohel, Shrijeet Panickar, Vijay Chincholkar, Santosh Mangalkar
INTRODUCTION: Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge...
October 2016: Indian Journal of Pathology & Microbiology
P Panagopoulos, N Papanas, E Maltezos
No abstract text is available yet for this article.
October 10, 2016: Expert Opinion on Pharmacotherapy
Ellie J C Goldstein, Diane M Citron, Kerin L Tyrrell, Elisa Leoncio, C Vreni Merriam
The comparative in vitro activity of tedizolid against 124 Bacteroides group species isolates, including carbapenem, metronidazole and piperacillin-tazobactam resistant strains, had an MIC90 of 2 μg/ml (range, 0.5-4 μg/ml) and was 1-4 times more active than linezolid that had an MIC90 of 8 μg/ml (range, 2-16 μg/ml).
October 3, 2016: Anaerobe
D J Biedenbach, S K Bouchillon, B Johnson, J Alder, D F Sahm
Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines...
September 27, 2016: European Journal of Clinical Microbiology & Infectious Diseases
Tarani Kanta Barman, Manoj Kumar, Tarun Mathur, Tridib Chaira, G Ramkumar, Vandana Kalia, Madhvi Rao, Manisha Pandya, Ajay Singh Yadav, Biswajit Das, Dilip J Upadhyay, Hamidullah, Rituraj Konwar, V Samuel Raj, Harpal Singh
RBx 11760, a bi-aryl oxazolidinone was investigated for antibacterial activity against Gram positive bacteria. The MIC90 (mg/L) of RBx 11760 and linezolid against Staphylococcus aureus were: 2 and 4, Staphylococcus epidermidis: 0.5 and 2, Enterococcus: 1 and 4, respectively. Similarly against Streptococcus pneumoniae MIC90 was: 0.5 and 2, respectively. In time-kill studies, RBx 11760, tedizolid and linezolid exhibited bacteriostatic effect except S. pneumoniae RBx 11760 showed 2-log10 kill at 4 X MIC while tedizolid and linezolid showed 2 log10 and 1...
September 19, 2016: Antimicrobial Agents and Chemotherapy
Shuguang Li, Yu Guo, Chunjiang Zhao, Hongbin Chen, Bijie Hu, Yunzhuo Chu, Zhijie Zhang, Yunjian Hu, Zhiyong Liu, Yan Du, Qiaodi Gui, Ping Ji, Ji Zeng, Bin Cao, Quan Fu, Rong Zhang, Zhongxin Wang, Chao Zhuo, Xianju Feng, Wei Jia, Yan Jin, Xuesong Xu, Kang Liao, Yuxing Ni, Yunsong Yu, Xiuli Xu, Zhidong Hu, Jin-E Lei, Qing Yang, Hui Wang
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 non-duplicate isolates (23.7% isolated from HAP, 46.8% from SSTI and 29.5% from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus (MRSA), 867 methicillin-sensitive S...
September 2, 2016: Journal of Medical Microbiology
Kyung-Hwa Park, Kerryl E Greenwood-Quaintance, Jayawant Mandrekar, Robin Patel
BACKGROUND: We compared tedizolid alone and with rifampin against rifampin and vancomycin plus rifampin in rat model of methicillin-resistant Staphylococcus aureus (MRSA) foreign body-associated osteomyelitis. METHODS: The study strain was a prosthetic joint infection-associated isolate. Steady-state pharmacokinetics for intraperitoneal administration of tedizolid, vancomycin, and rifampin were determined in uninfected rats. MRSA was inoculated into the proximal tibia, and a wire was implanted...
August 22, 2016: Antimicrobial Agents and Chemotherapy
William Palmer-Brown, Brian Dunne, Yannick Ortin, Mark A Fox, Graham Sandford, Cormac D Murphy
1. Fluorine plays a key role in the design of new drugs and recent FDA approvals included two fluorinated drugs, tedizolid phosphate and vorapaxar, both of which contain the fluorophenyl pyridyl moiety. 2. To investigate the likely phase I (oxidative) metabolic fate of this group, various fluorinated phenyl pyridine carboxylic acids were incubated with the fungus Cunninghamella elegans, which is an established model of mammalian drug metabolism. 3. (19)F NMR spectroscopy established the degree of biotransformation, which varied depending on the position of fluorine substitution, and GC-MS identified alcohols and hydroxylated carboxylic acids as metabolites...
August 19, 2016: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
Warren S Joseph, Darren Culshaw, Steven Anuskiewicz, Carisa De Anda, Philippe Prokocimer
BACKGROUND: Tedizolid phosphate, the prodrug of the oxazolidinone tedizolid, has been approved in a number of countries, including the United States, those in the European Union, and Canada, for treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Two Phase 3 trials demonstrated the noninferior efficacy of tedizolid (200 mg once daily for 6 days) to linezolid (600 mg twice daily for 10 days) in patients with ABSSSI. Because of the challenges of treating lower-extremity ABSSSI, the efficacy and safety of tedizolid and linezolid for treating lower extremity versus non-lower extremity infections were compared...
August 17, 2016: Journal of the American Podiatric Medical Association
John H Powers, Anita F Das, Carisa De Anda, Philippe Prokocimer
OBJECTIVES: Outcome assessments as clinical trial endpoints should be well-defined, reliable, and reflect meaningful treatment benefits. For acute bacterial skin and skin structure infections (ABSSSI) trials, recent recommendations suggest a primary endpoint of reduction in skin lesion area. Objectives were: evaluate ABSSSI lesion area measurement reliability, evaluate impact of various lesion area definitions on treatment effect size, and explore relationships between lesion area and pain...
September 2016: Contemporary Clinical Trials
E-M Klupp, A Both, C Belmar Campos, H Büttner, C König, M Christopeit, M Christner, M Aepfelbacher, H Rohde
Vancomycin-resistant enterococci (VRE) are of ever-increasing importance, most notably in high-risk patient populations. Therapy options are often limited for these isolates, and apart from tigecycline and daptomycin, oxazolidinone linezolid is frequently administered. The broad usage of linezolid, however, has driven the emergence of linezolid-resistant VRE strains (LR-VRE), further shortening therapeutic options. Second-generation oxazolidinone tedizolid has the advantage of being active against a specific subset of LR-VRE, i...
August 15, 2016: European Journal of Clinical Microbiology & Infectious Diseases
Rui Chen, Kai Shen, Xinying Chang, Toshiaki Tanaka, Li Li, Pei Hu
PURPOSE: Tedizolid phosphate is a new antibacterial agent under investigation for the treatment of Gram-positive infections in China. This study was conducted to assess the pharmacokinetic (PK) properties, oral bioavailability, and safety of once daily tedizolid phosphate 200 mg in Chinese subjects to support its further clinical development in China. METHODS: This Phase I single-center study, conducted in 16 healthy Chinese male subjects, consisted of a single-dose administration, 1:1 randomized, two-way, intravenous (IV)/oral (PO) crossover of tedizolid phosphate 200 mg (Part 1) and, after a 7-day washout, a nonrandomized, multiple-dose, 7-day tedizolid phosphate 200 mg once daily administration (IV for 3 days, PO for 4 days; Part 2)...
August 2016: Clinical Therapeutics
M Peñuelas, F J Candel, C Lejarraga, L López-González, J M Viñuela-Prieto, D López de Mendoza
OBJECTIVE: The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in Spain is approximately 20-30%. However, resistance to linezolid is rare, and the main reports are from nosocomial outbreaks. The objective of the present study was to compare the in vitro susceptibility of linezolid with that of tedizolid against MRSA isolates and methicillin-and linezolid-resistant isolates (MLRSA) mediated by the cfr gene. METHODS: The in vitro susceptibility of linezolid and tedizolid was determined using the E-test with 18 MRSA strains and 18 cfr-mediated MLRSA strains obtained from clinical isolates in the microbiology service of a tertiary university hospital...
October 2016: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
Michael A Pfaller, Robert K Flamm, Ronald N Jones, David J Farrell, Rodrigo E Mendes
Tedizolid and linezolid in vitro activities against 3,032 Gram-positive pathogens collected in Asia-Pacific, Eastern European, and Latin American medical centers during 2014 were assessed. The isolates were tested for susceptibility by the current reference broth microdilution methods. Due to concern over the effect of MIC endpoint criteria on the results of testing the oxazolidinones tedizolid and linezolid, MIC endpoint values were read by two methods: (i) reading the MIC at the first well where the trailing began without regard for pinpoint trailing, according to CLSI M07-A10 and M100-S26 document instructions for reading linezolid (i...
September 2016: Antimicrobial Agents and Chemotherapy
Adamantia Liapikou, Antoni Torres
INTRODUCTION: Hospital-acquired pneumonia (HAP) is one of the leading nosocomial infections worldwide and is associated with an elevated morbidity and mortality and increased hospital costs. Nevertheless, prompt and adequate antimicrobial treatment is mandatory following VAP development, especially in the face of multidrug resistant pathogens. AREAS COVERED: We searched Pubmed and site reports in English language of phase III clinical trials, between 2000-2016 referring to the antibiotic treatment of nosocomial pneumonia...
September 2016: Expert Opinion on Emerging Drugs
Shawn Flanagan, Jeffrey Litwin, Edward Fang, Philippe Prokocimer
Drug-induced prolongation of the QT interval on the electrocardiogram (ECG) infrequently results in Torsades de pointes, a potentially fatal arrhythmia. Therefore, thorough QT analysis of new drugs is a regulatory requirement. The objective of this phase 1 study was to assess the effects of oral tedizolid phosphate on the QT interval corrected with Fridericia's formula (QTcF) in healthy adult subjects. A single therapeutic dose (200 mg) and a supratherapeutic dose (1200 mg) of tedizolid phosphate were administered to characterise QTc changes following typical systemic exposure and with markedly higher exposures, respectively...
July 2016: International Journal of Antimicrobial Agents
Thomas P Lodise, Monique R Bidell, Shawn D Flanagan, Evan J Zasowski, Sonia L Minassian, Philippe Prokocimer
OBJECTIVES: Tedizolid is a novel oxazolidinone antibacterial. Oxazolidinones carry concerns for time-dependent myelosuppression. To further explore tedizolid's haematological tolerability, we analysed data from a 21 day study comparing safety and pharmacokinetics of tedizolid and linezolid. METHODS: This was a Phase 1 study in healthy volunteers comparing five treatments (each n = 8) over 21 days: tedizolid at 200, 300 or 400 mg once daily; linezolid at 600 mg twice daily; and placebo...
September 2016: Journal of Antimicrobial Chemotherapy
Arnold S Bayer, Wessam Abdelhady, Liang Li, Rachelle Gonzales, Yan Q Xiong
Tedizolid, a novel oxazolidinone, exhibits bacteriostatic activity through inhibition of protein synthesis. The efficacies of tedizolid, linezolid, and vancomycin were compared in a murine catheter-related biofilm infection caused by methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) strains engineered for bioluminescence. We observed significantly improved efficacy in terms of decreased S. aureus densities and bioluminescent signals in the tedizolid-treated group versus the linezolid- and vancomycin-treated groups in the model of infection caused by the MSSA and MRSA strains...
August 2016: Antimicrobial Agents and Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"